Attenuation of fibrosis in vitro and in vivo with SPARC siRNA

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Wang, Jiu Cun ^a,b   Lai, Syeling ^c   Guo, Xinjian ^b   Zhang, Xuefeng ^b   de Crombrugghe, Benoit ^d   Sonnylal, Sonali ^d   Arnett, Frank C ^b   Zhou, Xiaodong ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN TYPE 1; OSTEONECTIN; SMALL INTERFERING RNA; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG MECHANISM; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MOUSE; NONHUMAN; SKIN FIBROBLAST; SKIN FIBROSIS; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FIBROBLAST; FIBROSIS; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; GENETICS; LUNG; METABOLISM; PATHOLOGY; SKIN; TRANSGENIC MOUSE;

ANIMALS; CELLS, CULTURED; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; GENE KNOCK-IN TECHNIQUES; GENE SILENCING; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEONECTIN; PROTEIN-SERINE-THREONINE KINASES; PULMONARY FIBROSIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SKIN; TRANSFECTION;

EID: 77950528143     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2973     Document Type: Article

References (33)

1. Abdelaziz MM, Samman YS, Wali SO, Hamad MM. Treatment of idiopathic pulmonary fibrosis: is there anything new?. Respirology 2005, 10:284-289. 10.1111/j.1440-1843.2005.00712.x, 15955138.
2. Tome S, Lucey MR. Review article: Current management of alcoholic liver disease. Aliment Pharmacol Ther 2004, 19:707-714. 10.1111/j.1365-2036.2004.01881.x, 15043511.
3. Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007, 19:611-618. 10.1097/BOR.0b013e3282f13137, 17917543.
4. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995, 147:1759-1769. 1869942, 7495300.
5. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, Andoh TF, Lombardi DM, Schwartz SM, Bennett WM, Alpers CE, Sage EH, Johnson RJ, Couser WG. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int 1996, 50:1978-1989. 10.1038/ki.1996.520, 8943481.
6. Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, Sage EH, Zern MA. Expression of SPARC in normal and fibrotic livers. Hepatology 1995, 21:847-854.
7. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA 1992, 89:1281-1285. 10.1073/pnas.89.4.1281, 48433, 1311092.
8. Zhou X, Tan FK, Reveille JD, Wallis D, Milewicz DM, Ahn C, Wang A, Arnett FC. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 2002, 46:2990-2999. 10.1002/art.10601, 12428242.
9. Vuorio T, Kähäri VM, Black C, Vuorio E. Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. J Rheumatol 1991, 18:247-251.
10. Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM, Goldblum SE. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002, 29:2565-2570.
11. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology (Oxford) 2006, 45:1349-1355. 10.1093/rheumatology/kei277, 17050587.
12. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 2001, 19:816-827. 10.1016/S0945-053X(00)00133-5, 11223341.
13. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003, 14:3977-3988. 10.1091/mbc.E03-01-0001, 14517312.
14. Zhou X, Tan FK, Guo X, Wallis D, Milewicz DM, Xue S, Arnett FC. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor β1 in cultured normal human fibroblasts. Arthritis Rheum 2005, 52:257-261. 10.1002/art.20785, 15641096.
15. Strandjord TP, Madtes DK, Weiss DJ, Sage EH. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol 1999, 277:L628-635.
16. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003, 4:457-467. 10.1038/nrm1129, 12778125.
17. Duchaine TF, Slack FJ. RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol 2009, 16:61-66. 10.3747/co.v16i4.486, 2722055, 19672426.
18. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453. 10.1038/nrd2310, 17541417.
19. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138. 10.1038/nrd2742, 19180106.
20. Zhou XD, Tan FK, Guo X, Arnett FC. Attenuation of collagen synthesis with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. Arthritis Rheum 2006, 54:2626-2631. 10.1002/art.21973, 16871529.
21. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007, 56:334-344. 10.1002/art.22328, 17195237.
22. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292. 10.1056/NEJM199411103311907, 7935686.
23. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350-1358. 10.1056/NEJM200005043421807, 10793168.
24. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-β action on fibroblasts. Cytokine Growth Factor Rev 1997, 8:171-179. 10.1016/S1359-6101(97)00010-5, 9462483.
25. Chujo S, Shirasaki F, Kawara S, Inagaki Y, Kinbara T, Inaoki M, Takigawa M, Takehara K. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-β in a mouse fibrosis model. J Cell Physiol 2005, 203:447-456. 10.1002/jcp.20251, 15605379.
26. Zhou XD, Xiong MM, Tan FK, Guo XJ, Arnett FC. SPARC. An upstream regulator of connective tissue growth factor in response to transforming growth factor β stimulation. Arthritis Rheum 2006, 54:3885-3889. 10.1002/art.22249, 17133596.
27. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-β-signaling system. Mol Biol Cell 2003, 14:3977-3988. 10.1091/mbc.E03-01-0001, 206993, 14517312.
28. George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007, 14:790-803. 10.1038/sj.gt.3302929, 17344905.
29. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, Wang T, Sage EH. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 2004, 91:915-925. 10.1002/jcb.20008, 15034927.
30. Cutroneo KR, White SL, Phan SH, Ehrlich HP. Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J Cell Physiol 2007, 211:585-589. 10.1002/jcp.20972, 17387717.
31. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol 2007, 171:1104-1112. 10.2353/ajpath.2007.061273, 1988862, 17717147.
32. Kos K, Wong S, Tan B, Gummesson A, Jernas M, Franck N, Kerrigan D, Nystrom FH, Carlsson LM, Randeva HS, Pinkney JH, Wilding JP. Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. Diabetes 2009, 58:1780-1788. 10.2337/db09-0211, 2712789, 19509023.
33. Reding T, Wagner U, Silva AB, Sun LK, Bain M, Kim SY, Bimmler D, Graf R. Inflammation-dependent expression of SPARC during development of chronic pancreatitis in WBN/Kob rats and a microarray gene expression analysis. Physiol Genomics 2009, 38:196-204. 10.1152/physiolgenomics.00028.2009, 19435834.